ADDEX THERAPEUTICS TO RELEASE Q3 2020 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON NOVEMBER 3rd, 2020
November 02 2020 - 1:06AM
Geneva, Switzerland, November 2,
2020 – Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a
leading company pioneering allosteric modulation-based drug
discovery and development, will discuss its Q3 2020 financial
results, provide a business update and review its pipeline during a
teleconference and webcast for investors, analysts and the media on
Tuesday, November 3, 2020 at 16:00 CET (15:00 GMT/10:00 ET).
Title:
Addex Q3 2020 Financial Results Conference
CallDate:
November 3,
2020Time:
16:00 CEST (15:00 GMT/10:00 ET)
Joining the Conference
Call:
1. In the 10 minutes prior to
the call start time, call the appropriate participant dial-in
number.
Dial-In Numbers:
-
Switzerland
+ 41445806522
-
UK
+ 442030092470
-
USA
+ 18774230830
Link for other countries
2. Provide the operator with
the Participant PIN Code: 48937768#
Joining the Live Event
Online:
- In the 10 minutes prior to the call start time, sign in online
by following this Webex Link
- Password : Welcome
About Addex Therapeutics:
Addex Therapeutics is a clinical-stage
pharmaceutical company focused on the development and
commercialization of an emerging class of novel orally available
small molecule drugs known as allosteric modulators for
neurological disorders. Allosteric modulators offer several
potential advantages over conventional non-allosteric molecules and
may offer an improved therapeutic approach to conventional
"orthosteric" small molecule or biological drugs. Addex's
allosteric modulator drug discovery platform targets receptors and
other proteins that are recognized as essential for therapeutic
intervention. Addex's lead drug candidate, dipraglurant (mGlu5
negative allosteric modulator or NAM), is scheduled to enter a
pivotal registration clinical trial for Parkinson’s disease
levodopa induced dyskinesia (PD-LID). In parallel, dipraglurant's
therapeutic use in dystonia is being investigated in preclinical
models. Addex's second clinical program ADX71149 (mGlu2 positive
allosteric modulator or PAM), developed in collaboration with
Janssen Pharmaceuticals, Inc., is scheduled to enter a Phase 2a
proof of concept clinical study for the treatment of epilepsy.
Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM
for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM
for Parkinson’s disease and mGlu3 PAM for neurodegenerative
disorders.
Press Contacts:
Tim DyerChief Executive OfficerTelephone: +41 22 884 15
55Email: PR@addextherapeutics.com |
Mike SinclairPartner, Halsin Partners+44 (0)20 7318
2955msinclair@halsin.com |
Forward Looking
Statements:Certain statements made in this announcement
are forward-looking statements including with respect to the
anticipated timing of the Company’s clinical trials and the
reporting of data therefrom. These forward-looking statements are
not historical facts but rather are based on the Company's current
expectations, estimates, and projections about its industry; its
beliefs; and assumptions. Words such as 'anticipates,' 'expects,'
'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar
expressions are intended to identify forward-looking statements.
These statements are not guarantees of future performance and are
subject to known and unknown risks, uncertainties, and other
factors, some of which are beyond the Company's control, are
difficult to predict, and could cause actual results to differ
materially from those expressed or forecasted in the
forward-looking statements, including relays resulting from the
COVID-19 pandemic and healthcare regulatory considerations. The
Company cautions securityholders and prospective securityholders
not to place undue reliance on these forward-looking statements,
which reflect the view of the Company only as of the date of this
announcement. The forward-looking statements made in this
announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
Geneva, Switzerland, November 2nd,
2020 – Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a
leading company pioneering allosteric modulation-based drug
discovery and development, will discuss its Q3 2020 financial
results, provide a business update and review its pipeline during a
teleconference and webcast for investors, analysts and the media on
Tuesday, November 3 at 16:00 CET (15:00 GMT/10:00 ET).
Title:
Addex Q3 2020 Financial Results Conference
CallDate:
August 12,
2020Time:
16:00 CEST (15:00 GMT/10:00 ET)
Joining the Conference
Call:
1. In the 10 minutes prior to
the call start time, call the appropriate participant dial-in
number.
Dial-In Numbers:
-
Switzerland
+ 41445806522
-
UK
+ 442030092470
-
USA
+ 18774230830
Link for other countries
2. Provide the operator with
the Participant PIN Code: 48937768#
Joining the Live Event
Online:
- In the 10 minutes prior to the call start time, sign in online
by following this Webex Link
- Password : Welcome
-
About Addex Therapeutics:
Addex Therapeutics is a clinical-stage
pharmaceutical company focused on the development and
commercialization of an emerging class of novel orally available
small molecule drugs known as allosteric modulators for
neurological disorders. Allosteric modulators offer several
potential advantages over conventional non-allosteric molecules and
may offer an improved therapeutic approach to conventional
"orthosteric" small molecule or biological drugs. Addex's
allosteric modulator drug discovery platform targets receptors and
other proteins that are recognized as essential for therapeutic
intervention. Addex's lead drug candidate, dipraglurant (mGlu5
negative allosteric modulator or NAM), is ready to start a
pivotal registration clinical trial for Parkinson’s disease
levodopa induced dyskinesia (PD-LID) subject to restrictions in US
healthcare system associated with the global Covid-19 crisis being
lifted. Addex is also investigating dipraglurant's therapeutic use
in blepharospasm (a type of dystonia), with exploratory clinical
studies scheduled to begin in early 2021. Addex's third clinical
program, ADX71149 (mGlu2 positive allosteric modulator or PAM),
developed in collaboration withJanssen Pharmaceuticals, Inc, is
scheduled to enter a phase 2a proof of concept clinical study
for the treatment of epilepsy in early 2021. Addex’s GABAB PAM
program has been licensed to Indivior PLC for the treatment of
addiction. Preclinical programs include GABAB PAM for CMT1A,
mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders,
mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for
neurodegenerative disorders.
Press Contacts:
Tim DyerChief Executive OfficerTelephone: +41 22 884 15
55Email: PR@addextherapeutics.com |
Mike SinclairPartner, Halsin Partners+44 (0)20 7318
2955msinclair@halsin.com |
Forward Looking
Statements:Certain statements made in this announcement
are forward-looking statements including with respect to the
anticipated timing of the Company’s clinical trials and the
reporting of data therefrom. These forward-looking statements are
not historical facts but rather are based on the Company's current
expectations, estimates, and projections about its industry; its
beliefs; and assumptions. Words such as 'anticipates,' 'expects,'
'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar
expressions are intended to identify forward-looking statements.
These statements are not guarantees of future performance and are
subject to known and unknown risks, uncertainties, and other
factors, some of which are beyond the Company's control, are
difficult to predict, and could cause actual results to differ
materially from those expressed or forecasted in the
forward-looking statements, including relays resulting from the
COVID-19 pandemic and healthcare regulatory considerations. The
Company cautions securityholders and prospective securityholders
not to place undue reliance on these forward-looking statements,
which reflect the view of the Company only as of the date of this
announcement. The forward-looking statements made in this
announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Apr 2023 to Apr 2024